Literature DB >> 16736756

Biocompatible nanotemplate-engineered nanoparticles containing gadolinium: stability and relaxivity of a potential MRI contrast agent.

Donghua Zhu1, R D White, Peter A Hardy, Natthida Weerapreeyakul, Khaetthareeya Sutthanut, Michael Jay.   

Abstract

In this article, we use a nanotemplate engineering approach to prepare biodegradable nanoparticles composed of FDA-approved materials and possessing accessible gadolinium (Gd) atoms and demonstrate their potential as a Magnetic Resonance Imaging (MRI) contrast agent. Nanoparticles containing dimyristoyl phosphoethanolamine diethylene triamine penta acetate (PE-DTPA) were prepared using 3.5 mg of Brij 78, 2.0 mg of emulsifying wax and 0.5 mg of PE-DTPA/ml from a microemulsion precursor. After the addition of GdCl3, the presence of Gd on the surface of nanoparticles was characterized using inductively coupled plasma atomic emission spectroscopy and Scanning Transmission Electron Microscopy (STEM). The in vitro relaxivities of the PE-DTPA-Gd nanoparticles in different media were assessed at different field strengths. The conditional stability constant of Gd binding to the nanoparticles was determined using competitive spectrophotometric titration. Transmetallation kinetics of the gadolinium ion from PE-DTPA-Gd nanoparticles with zinc as the competing ionic was measured using the relaxivity evolution method. Nanoparticles with a diameter of approximately 130 nm possessing surface chelating functions were made from GRAS (Generally Regarded As Safe) materials. STEM demonstrated the uniform distribution of Gd3+ on the surface of the nanoparticles. The thermodynamic binding constant for Gd3+ to the nanoparticles was approximately 10(18) M(-1) and transmetallation studies with Zn2+ yielded kinetic constants K1 and K(-1) of 0.033 and 0.022 1/h, respectively, with an equilibrium constant of 1.5. A payload of approximately 10(5) Gd/nanoparticle was achieved; enhanced relaxivities were observed, including a pH dependence of the transverse relaxivity (r2). Nanoparticles composed of materials that have been demonstrated to be hemocompatible and enzymatically metabolized and possessing accessible Gd ions on their surface induce relaxivities in the bulk water signal that make them potentially useful as next-generation MRI tumor contrast enhancement agents.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16736756     DOI: 10.1166/jnn.2006.169

Source DB:  PubMed          Journal:  J Nanosci Nanotechnol        ISSN: 1533-4880


  8 in total

1.  Cardiac magnetic resonance imaging of rapid VCAM-1 up-regulation in myocardial ischemia-reperfusion injury.

Authors:  Stuart M Grieve; Jacob Lønborg; Jawad Mazhar; Timothy C Tan; Edwin Ho; Chia-Chi Liu; William Lay; Anthony J Gill; Philip Kuchel; Ravinay Bhindi; Gemma A Figtree
Journal:  Eur Biophys J       Date:  2012-09-28       Impact factor: 1.733

2.  Magnetic Nanoparticles for Early Detection of Cancer by Magnetic Resonance Imaging.

Authors:  Wenbin Lin; Taeghwan Hyeon; Gregory M Lanza; Miqin Zhang; Thomas J Meade
Journal:  MRS Bull       Date:  2009-06       Impact factor: 6.578

3.  Gadolinium-conjugated TiO2-DNA oligonucleotide nanoconjugates show prolonged intracellular retention period and T1-weighted contrast enhancement in magnetic resonance images.

Authors:  Tatjana Paunesku; Tianyi Ke; Rohan Dharmakumar; Nicole Mascheri; Aiguo Wu; Barry Lai; Stefan Vogt; Jörg Maser; Kenneth Thurn; Barbara Szolc-Kowalska; Andrew Larson; Raymond C Bergan; Reed Omary; Debiao Li; Zheng-Rong Lu; Gayle E Woloschak
Journal:  Nanomedicine       Date:  2008-06-24       Impact factor: 5.307

4.  Functionalized magnetic resonance contrast agent selectively binds to glycoprotein IIb/IIIa on activated human platelets under flow conditions and is detectable at clinically relevant field strengths.

Authors:  Constantin von Zur Muhlen; Dominik von Elverfeldt; Robin Paul Choudhury; Janine Ender; Ingo Ahrens; Meike Schwarz; Jürgen Hennig; Christoph Bode; Karlheinz Peter
Journal:  Mol Imaging       Date:  2008 Mar-Apr       Impact factor: 4.488

5.  In vivo performance of a liposomal vascular contrast agent for CT and MR-based image guidance applications.

Authors:  Jinzi Zheng; Jubo Liu; Mike Dunne; David A Jaffray; Christine Allen
Journal:  Pharm Res       Date:  2007-03-21       Impact factor: 4.580

6.  Biodistribution of newly synthesized PHEA-based polymer-coated SPION in Sprague Dawley rats as magnetic resonance contrast agent.

Authors:  Junsung Park; Wonkyung Cho; Hee Jun Park; Kwang-Ho Cha; Dae-Chul Ha; Youn-Woong Choi; Ha-Young Lee; Sun-Hang Cho; Sung-Joo Hwang
Journal:  Int J Nanomedicine       Date:  2013-10-31

Review 7.  An approach to molecular imaging of atherosclerosis, thrombosis, and vascular inflammation using microparticles of iron oxide.

Authors:  Martina A McAteer; Asim M Akhtar; Constantin von Zur Muhlen; Robin P Choudhury
Journal:  Atherosclerosis       Date:  2009-10-12       Impact factor: 5.162

8.  Visualization of activated platelets by targeted magnetic resonance imaging utilizing conformation-specific antibodies against glycoprotein IIb/IIIa.

Authors:  Constantin von zur Muhlen; Karlheinz Peter; Ziad A Ali; Jurgen E Schneider; Martina A McAteer; Stefan Neubauer; Keith M Channon; Christoph Bode; Robin P Choudhury
Journal:  J Vasc Res       Date:  2008-05-31       Impact factor: 1.934

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.